Should I start alendronate after a recent vertebral compression fracture?

Yes, start alendronate (or another bisphosphonate) after a vertebral compression fracture

You should initiate pharmacologic treatment with alendronate or another bisphosphonate (risedronate, zoledronic acid) immediately after a vertebral compression fracture to prevent subsequent fractures. A recent vertebral compression fracture places you at very high risk for additional fractures—both vertebral and non-vertebral—and bisphosphonates have the strongest evidence for reducing this risk.

Why Bisphosphonates Are First-Line After Vertebral Fracture

Alendronate and risedronate are recommended as first-choice agents because they are well-tolerated, have extensive clinical experience, are available as generics (low cost), and most importantly, have demonstrated reduction in vertebral, non-vertebral, AND hip fractures 1. The evidence is particularly robust:

• Vertebral fracture reduction: Alendronate reduces new vertebral fractures by 47-48% over 3 years 2, 3, 4
• Clinical fracture reduction: 26-28% reduction in all clinical fractures 2, 3
• Hip fracture reduction: 51% reduction in hip fractures 2, 4
• Early benefit: Fracture risk reduction becomes evident within 12 months of starting treatment 3

The 2017 EULAR/EFORT guidelines specifically state that alendronate and risedronate are first-choice agents for patients with recent fragility fractures 1.

Alternative Bisphosphonates

If you cannot tolerate oral alendronate due to:

• GI intolerance (esophagitis, dyspepsia)
• Inability to remain upright for 30-60 minutes
• Esophageal abnormalities (stricture, achalasia)
• Malabsorption issues
• Poor adherence/dementia

Then switch to:

• Zoledronic acid (IV yearly) 1
• Denosumab (subcutaneous every 6 months) 1

Both alternatives also reduce vertebral, non-vertebral, and hip fractures 1.

When to Consider Anabolic Agents Instead

For patients at VERY HIGH fracture risk, consider starting with anabolic agents (teriparatide, romosozumab, abaloparatide) rather than bisphosphonates 5. Very high risk includes:

• Multiple vertebral fractures (≥2)
• Very low T-scores (≤-3.0)
• Recent hip fracture
• Fracture while on bisphosphonate therapy

The 2020 AACE guidelines note that anabolic agents "may be preferable for patients at very high risk of fracture as initial therapy" 5. However, you must transition to a bisphosphonate after completing the anabolic agent course to maintain bone gains 5.

Critical Pre-Treatment Steps

Before starting alendronate:

1. Correct vitamin D deficiency: Achieve 25(OH)D >32 ng/mL (some recommend 40-50 ng/mL) 6

   • Vitamin D deficiency attenuates bisphosphonate efficacy and increases hypocalcemia risk 6
   • Use vitamin D3 1000-2000 IU daily for maintenance

2. Ensure adequate calcium intake: 1000-1200 mg/day total (diet + supplements if needed) 1

3. Check renal function: Alendronate should be used with caution if GFR <35 mL/min 5

4. Complete necessary dental work: Osteonecrosis of the jaw risk is very rare (<1 per 100,000 person-years) but increased with recent dental surgery 6

Dosing and Administration

Alendronate 70 mg once weekly (oral) 5:

• Take after overnight fast, first thing in morning
• Swallow with full glass (200 mL) of plain water
• Remain upright for 30-60 minutes
• Wait 30 minutes before eating, drinking, or taking other medications

Treatment Duration

Treat for at least 3-5 years initially 1, 7. The American College of Physicians recommends 5 years of treatment 7. After this period:

• Reassess fracture risk
• Consider continuing if still at high risk
• Some patients may benefit from treatment beyond 5 years 1

Common Pitfalls to Avoid

1. Delaying treatment: Don't wait for DEXA results if a fragility fracture has occurred—the fracture itself indicates treatment need 1

2. Inadequate vitamin D repletion: This is endemic in fracture patients and must be corrected before starting bisphosphonates 1, 6

3. Poor adherence: Oral bisphosphonates have complex dosing requirements. If adherence is questionable, use IV zoledronic acid or subcutaneous denosumab instead 1

4. Forgetting sequential therapy: If you start with an anabolic agent for very severe osteoporosis, you MUST transition to a bisphosphonate afterward to prevent bone loss 5

Evidence Quality Note

The recommendation for bisphosphonates after vertebral fracture is supported by high-quality evidence from multiple large randomized controlled trials 2, 3, 4 and strong guideline recommendations from major societies 5, 1, 7. The Fracture Intervention Trial specifically demonstrated that alendronate is effective regardless of age, baseline BMD, or number of existing vertebral fractures 8, 4.